RESEARCH & DEVELOPMENT
We continue to build our treatment portfolio with a current focus on oncology within the United States.
Globally, our pipeline includes a robust portfolio of treatments for various therapeutic areas.
At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today’s challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients.
Servier’s pipeline includes many oncology assets at varying stages of clinical development.
PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3; FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor; MTAP: Methylthioadenosine Phosphorylase; IDH: Isocitrate dehydrogenase; AYA: Adolescents and Young Adults; MOA: Mode of Action